|
|
|
|
|
|
From early-stage R&D to method development and CMC scale-up, analytical labs are essential for ensuring therapeutic quality and safety. They address identity, purity, potency, stability, and safety while assessing critical quality attributes. As regulatory demands grow and pipelines diversify, integrated analytical workflows and traceable data are vital to reducing risk, improving reproducibility, and upholding scientific rigor throughout development and scale-up.
|
|
|
|
|
Eliminating analytical bottlenecks is critical to accelerating drug discovery, reducing costs, and strengthening data confidence. Connected solutions that unify instruments, data, and teams enable faster and more consistent decision-making.
|
|
|
|
|
Bringing human-relevant models into preclinical drug screening improves efficiency and increases the likelihood of clinical success. Scaling their impact requires technologies that address the practical challenges of 3D cell culture. Integrated innovations now enable this transformation, accelerating progress in drug discovery.
|
|
|
|
|
Scaling gene therapy requires precision, consistency, and actionable data. From ultracentrifugation to advanced mass spectrometry, integrated solutions support improved yield, purity, and characterization of adeno-associated viruses (AAV).
|
|
|
|
|
Robust CLD is essential for producing high-quality monoclonal and multi-specific antibodies. From clone selection to Master Cell Banking, each step affects scalability and success. Explore the integrated automation, analytics, and digital solutions to streamline CLD and accelerate biotherapeutic development.
|
|
|
|
|
Several gene therapies use modified adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target cells. Learn the solution that resolves monomers from dimers across various AAV serotypes and reduces sample consumption by up to 90% compared to traditional SEC columns, accelerating development and reducing costs.
|
|
|
|
|
Discover how spatial profiling and advanced imaging tools are transforming drug discovery, featuring Wayne Stallaert’s lab’s work on cell cycle mapping and biomarker insights in cancer research.
|
|
|
|
|
|
|
|
|
|
|
Join our webinar on October 9th to learn more about developing novel gene editing to accelerate therapies for ultra-orphan conditions, creating scalable models for efficient manufacturing and broader patient access, and formulating regulatory and clinical strategies to address rare disease challenges. Register today!
|
|
|
